Browsing tag:


On February 10, 2104 a substantial financial deal was announced by Melinta Therapeutics involving their projected blockbuster antibiotic Delafloxacin. A whopping 70 million dollar Series 3 equity financing deal was revealed, with various investors taking part, including Vatera Healthcare Partners. This extraordinary financing will be appropriated largely to advance the continued development, assessment and eventual[…]

Read More

Linezolid is a synthetic antibiotic used for the treatment of serious infections caused by Gram-positive bacteria that are resistant to several other antibiotics. A member of the oxazolidinone class of drugs, Linezolid is active against most Gram-positive bacteria that cause disease, including streptococci, vancomycin-resistant enterococci (VRE), and methicillin-resistant Staphylococcus aureus (MRSA). MRSA is especially troublesome[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service